FDA Approves Labcorp's NAbCyte Anti-AAVRh74var HB-FE, Companion Diagnostic To Determine Patient Eligibility For Treatment With Beqvez (Fidanacogene Elaparvovec-dzkt), Pfizer's Recently FDA-Approved Hemophilia B Gene Therapy
FDA Approves Labcorp's NAbCyte Anti-AAVRh74var HB-FE, Companion Diagnostic To Determine Patient Eligibility For Treatment With Beqvez (Fidanacogene Elaparvovec-dzkt), Pfizer's Recently FDA-Approved Hemophilia B Gene Therapy
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.